Clinical findings at screening for patients who did and did not develop IFRS after transplantation
| All at Pre-HCT Screen | No Post-HCT IFRS | Post-HCT IFRS | P Value | |
|---|---|---|---|---|
| No. | 100 | 98 | 2 | |
| ENT risk estimate (No.) (frequency) | ||||
| At risk | 29 (29%) | 28 (29%) | 1 (50%) | .61 |
| Low risk | 67 (67%) | 62 (63%) | 1 (50%) | |
| Not evaluated | 4 (4%) | 8 (8%) | 0 | |
| ANC at imaging (mean) | 2510 ± 5568 | 2524 ± 5622 | 1800 ± 1697 | .86 |
| Transplant donor (No.) (frequency) | ||||
| Allogenic | 66 (66%) | 65 (66%) | 1 (50%) | 1 |
| Autologous | 34 (34%) | 33 (34%) | 1 (50%) | |
| Disease status at transplantation (No.) (frequency) | ||||
| Complete remission | 82 (82%) | 80 (80%) | 2 (100%) | 1 |
| Active disease | 18 (18%) | 18 (18%) | ||
| T-cell depletion (No.) (frequency) | 2 (2%) | 2 (2%) | 0 | 1 |
| GVHD II–IV (No.) (frequency) | 15 (15%) | 15 (15%) | 0 | 1 |
Note:—ANC indicates absolute neutrophil count.